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Abstract Alzheimer’s disease (AD) and Parkinson’s dis-
ease (PD) are the most common causes of dementia and
movement disorders in the elderly. While progressive
accumulationofoligomericamyloid-bprotein(Ab)hasbeen
identiﬁed as one of the central toxic events in AD leading to
synaptic dysfunction, accumulation of a-synuclein (a-syn)
resulting in the formation of oligomers has been linked to
PD. Most of the studies in AD have been focused on inves-
tigating the role of Ab and Tau; however, recent studies
suggest that a-syn might also play a role in the pathogenesis
of AD. For example, fragments of a-syn can associate with
amyloid plaques and Ab promotes the aggregation of a-syn
in vivo and worsens the deﬁcits in a-syn tg mice. Moreover,
a-synhasalsobeenshowntoaccumulateinlimbicregionsin
AD,Down’ssyndrome,andfamilialADcases.Abanda-syn
mightdirectlyinteractunderpathologicalconditionsleading
to the formation of toxic oligomers and nanopores that
increase intracellular calcium. The interactions between Ab
and a-syn might also result in oxidative stress, lysosomal
leakage, and mitochondrial dysfunction. Thus, better
understanding the steps involved in the process of Ab and
a-syn aggregation is important in order to develop inter-
vention strategies that might prevent or reverse the accu-
mulation of toxic proteins in AD.
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Introduction to the Pathogenesis of AD
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are
the most common causes of dementia and movement dis-
orders in the elderly. While progressive accumulation of
amyloid-b protein (Ab) oligomers has been identiﬁed as
one of the central toxic events in AD leading to synaptic
dysfunction (Klein et al. 2001; Walsh and Selkoe 2004;
Glabe 2005), accumulation of a-synuclein (a-syn) resulting
in the formation of oligomers has been linked to PD
(Giasson et al. 2000; Lee et al. 2001; Lashuel et al. 2002;
Hashimoto et al. 2003b; Tsigelny et al. 2007). Alzheimer’s
disease and PD overlap in a heterogeneous group of dis-
orders denominated Lewy body disease (LBD) (McKeith
et al. 2005) where both Ab and a-syn accumulate in the
brain. Several lines of evidence now support a role for
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DOI 10.1007/s12640-009-9073-6a-syn not only in PD but also in additional disorders
including AD, multiple system atrophy (MSA), and others
(Trojanowski et al. 1998).
Alzheimer’s disease continues to be the leading cause of
dementia in the aging population (Ashford 2004). Over 5
million people live with this devastating neurological
condition and it is estimated that the US will experience an
average 50% increase in patients with AD by the year 2025
(Hebert et al. 2004). Alzheimer’s disease is a progressive
neurodegenerative disorder that speciﬁcally damages lim-
bic structures, the association neocortical pathways (Hof
and Morrison 1991; Masliah et al. 1993; Braak and Braak
1994; Hof and Morrison 1994), and the cholinergic system
(Perry et al. 1978; Perry 1995). Although the key neuro-
pathological diagnostic features of AD are the presence of
plaques—composed of amyloid-b (Ab) peptides (Selkoe
1990)—and tangles containing the microtubule binding
protein Tau (Trojanowski et al. 1993), the neurodegener-
ative process in AD probably initiates with damage to the
synaptic terminals (Scheff et al. 1990; Terry et al. 1991;
Masliah and Terry 1994). It has been postulated that the
early synaptic pathology leads to axonal abnormalities
(Goldstein et al. 2003), spine (Spires et al. 2005) and
dendritic atrophy (Moolman et al. 2004), and eventually
neuronal loss (Terry et al. 1991; Mucke et al. 2000).
Therefore, disruption of the mechanisms involved in
modulating synaptic plasticity might be responsible for the
characteristic cognitive deﬁcits in AD patients and as such
represent an important target for treatment development.
Although the precise mechanisms leading to neurode-
generation in AD are not completely understood, several
lines of investigation indicate that alterations in the amy-
loid precursor protein (APP), resulting in the accumulation
of amyloid-b protein (Ab) and APP C-terminal products,
might play a key role in the pathogenesis of AD (Selkoe
1994a, b; Sisodia and Price 1995; Sinha et al. 2000;
Kamenetz et al. 2003) (Fig. 1). Several products are
derived from APP through alternative proteolytic cleavage
pathways, and enormous progress has recently been made
in identifying the enzymes involved (Selkoe 1999; Sinha
et al. 1999; Vassar et al. 1999; Cai et al. 2001; Luo et al.
2001).
While most research has been centered at investigating
the role of APP/Ab and Tau in the pathogenesis of AD,
however, recent studies suggest that a-syn might also play
a role in the pathogenesis of this neurodegenerative dis-
order (Iwai et al. 1995a; Iwai 2000) (Fig. 2).
The Synuclein Family of Proteins in Health and Disease
a-Synuclein is an abundant presynaptic molecule (Iwai
et al. 1995b) that plays a role in modulating vesicular
synaptic release (Murphy et al. 2000). Synucleins belong
to a family of related proteins including a-, b-, and c-syn.
a-Synuclein belongs to a class of so-called naturally
unfolded proteins (Lansbury 1999; Wright and Dyson
1999) (Fig. 3). a-Synuclein contains a highly amyloido-
genic hydrophobic domain in the N-terminus region (aa
60–95) (Fig. 3) which is partially absent in b-syn and
might explain why b-syn has a reduced ability to self-
aggregate and form oligomers and ﬁbrils (Hashimoto
et al. 2001; Uversky et al. 2002). Moreover, previous
studies have shown that b-syn interacts with a-syn and is
capable of preventing a-syn aggregation and related def-
icits both in vitro and in vivo (Hashimoto et al. 2001).
Overall, synucleins are believed to be involved in regu-
lation of synaptic plasticity and dopamine neurotrans-
mitter release (Murphy et al. 2000).
a-Synuclein plays a role in synaptic adaptations,
including synaptic plasticity during development, learning
(Clayton and George 1998), and regulation of synaptic
vesicle mobilization at nerve terminals (Cabin et al. 2002).
Additionally, previous studies have shown that a-syn may
have important non-synaptic physiological functions that
occur through interactions with other molecules such as the
scaffolding protein Sept4 (Ihara et al. 2007) and the syn-
aptic vesicle protein cysteine-strong protein-a (CSPa)
Fig. 1 Schematic representation of the metabolism of APP and the
formation of Ab aggregates
Fig. 2 Role of the interactions between Ab, a-syn, and Tau in the
pathogenesis of AD and LBD
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123(Chandra et al. 2005). a-Synuclein has been implicated in
the pathogenesis not only of LBD (Trojanowski et al. 1998;
Hashimoto and Masliah 1999) but also of other disorders
with parkinsonism, including MSA (Spillantini et al. 1998;
Wakabayashi et al. 1998b; Wakabayashi et al. 1998a).
These disorders are collectively referred to as synuclein-
opathies (Hardy and Gwinn-Hardy 1998) and might share
common pathogenic pathways that promote toxic conver-
sion of a-syn.
Various lines of evidence support the contention that
abnormal aggregates arise from a partially folded inter-
mediate precursor that contains hydrophobic patches. It has
been proposed that the intermediate a-syn oligomers form
annular protoﬁbrils and pore-like structures (Ding et al.
2002; Volles and Lansbury 2002; Lashuel et al. 2003;
Rochet et al. 2004; Tsigelny et al. 2007) (Fig. 3). The
mechanisms through which monomeric a-syn converts into
a toxic oligomer and later into ﬁbrils is currently under
intense investigation. Recent studies suggest that a-syn
oligomerization might occur on the membrane and
involves interactions between hydrophobic residues of the
amphipathic a-helices of a-syn (Zhu et al. 2003). These
studies indicate that the hydrophobic lipid-binding domains
in the N-terminal region might be important in modulating
a-syn aggregation (Conway et al. 1998; Lansbury 1999;
Uversky et al. 2001; Jao et al. 2004).
Molecular modeling and molecular dynamic simulations
showed that a-syn homodimers could adopt non-propa-
gating (head-to-tail) and propagating (head-to-head) con-
formations (Tsigelny et al. 2007) (Fig. 3). Propagating
a-syn dimers on the membrane incorporate additional
a-syn molecules, leading to the formation of pentamers and
hexamers, which form rings suggestive of pore-like struc-
tures (Tsigelny et al. 2007) (Fig. 3). Oligomers form
complexes in the membranes of neurons that facilitate
abnormal calcium currents that might disturb synaptic and
neuronal function leading to neurodegeneration (Danzer
et al. 2007).
In conclusion, it is likely that a-syn oligomers might be
responsible for the neurodegenerative process in LBD/PD.
The Lewy bodies (LBs), which primarily contain a-syn
ﬁbrils, might represent a cellular mechanism to isolate
more toxic oligomers. The a-syn oligomers most likely
associate with the neuronal membranes and synapses,
interfering with neurotransmission and plasticity. Thus,
better understanding the steps involved in the process of
a-syn aggregation is important in order to develop inter-
vention strategies that might prevent or reverse a-syn
oligomerization and toxic conversion.
Disease Models, Knockouts, Assays
APP tg Animal Models of AD
The main focus of the following sections in AD will be on
models involving amyloid deposition and Tau hyper-
phosphorylation. In AD, mutations in PS1 and 2 and
polymorphisms in apolipoprotein E (ApoE) have been also
linked with AD and as such are important targets. Recently
developed tg animal models have shown that it is possible
to reproduce certain aspects of AD pathology over a shorter
period of time (Masliah et al. 1996b; Games et al. 1997;
Price et al. 2000). In one such model, the platelet-derived
growth factor (b chain) (PDGF-b) promoter drives an
alternatively spliced human APP (hAPP) minigene
(PDAPP) encoding mutated V ? F hAPP695, 751, 770
(Games et al. 1995; Rockenstein et al. 1995). This confers
Fig. 3 Molecular dynamics of
a-syn structure and progressive
aggregation leading to the
formation of toxic oligomers
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123a high ratio of mRNA encoding mutated hAPP versus wt
mouse APP (Rockenstein et al. 1995) that promotes
development of typical amyloid plaques, dystrophic neu-
rites, loss of presynaptic terminals, astrocytosis, and
microgliosis (Games et al. 1995; Masliah et al. 1996b;
Games et al. 1997).
Other models have expressed mutant hAPP under the
regulatory control of either the human or murine (m)Thy-1
promoter (Andra et al. 1996; Sturchler-Pierrat et al. 1997;
Moechars et al. 1999; Bornemann and Staufenbiel 2000)o r
the protease-resistant prion protein (PrP) promoter (Hsiao
et al. 1996; Borchelt et al. 1997). Amyloid deposition
begins at 12 months of age; however, co-expression of
mutant PS1 accelerates amyloid deposition, beginning at
4 months of age (Borchelt et al. 1996; Borchelt et al. 1997;
Holcomb et al. 1998). Another more recently developed
model, where APP is also expressed under the control of
the PrP promoter, displays even earlier onset of amyloid
deposition, starting at 3 months and progressing to mature
plaques and neuritic pathology from 5 months of age,
accompanied by high levels of Ab1–42 (Chishti et al. 2001).
While the PrP promoter has provided several models that
mimic aspects of familial AD (FAD), other promoters
targeting expression of APP to neurons provide alternative
models demonstrating pathology that recapitulate similar
and additional aspects of FAD. In this regard, we have
generated lines of tg mice expressing hAPP751 cDNA
containing the London (V717I) and Swedish (K670M/
N671L) mutations under the regulatory control of the
murine (m)Thy-1 gene (mThy1-hAPP751) (Rockenstein
et al. 2001). Therefore, while expression of mutant hAPP
under the PDGF-b promoter results in the production of
diffuse (and some mature) plaques (Games et al. 1995;
Mucke et al. 2000), tg expression of mutant hAPP under
the mThy-1 (Andra et al. 1996) and PrP (Hsiao et al. 1996;
Borchelt et al. 1997) promoters favors the formation of
mature plaques in the hippocampus and neocortex. This
suggests that the differential patterns of Ab deposition
might be dependent on the speciﬁc neuronal populations
selected by the promoter, levels of expression and topo-
graphical distribution of the transgene, and levels of Ab1–40
and Ab1–42. Consistent with this, in FAD and Down syn-
drome, production of high levels of Ab1–42 results in early
plaque formation (Citron et al. 1997). This suggests that
early age of onset and plaque formation depends on high
levels of Ab1–42 production (Rockenstein et al. 2001).
More recent models have been focused toward modeling
the role of Ab protoﬁbril generation and other mutations in
APP in the pathogenesis of AD. Of them, the most inter-
esting are those expressing APP bearing the Arctic muta-
tion. These mice rapidly develop extensive plaque
formation (Cheng et al. 2004). For a review of these and
additional tg models of neurodegenerative disease, please
visit the Alzheimer’s Forum website at: http://www.alz
forum.org/res/com/tra.
a-Synuclein Transgenic Models of PD and LBD
Since progressive intraneuronal aggregation of a-syn has
been proposed to play a central role in the pathogenesis of
PD and related disorders (Hashimoto and Masliah 1999;
Trojanowski and Lee 2000; Volles and Lansbury 2002),
most tg models have been focused at investigating the in
vivo effects of a-syn accumulation utilizing neuron-spe-
ciﬁc promoters. Several recent reviews have been pub-
lished addressing this subject (Hashimoto et al. 2003a;
Fernagut and Chesselet 2004). Among these models,
overexpression of wt a-syn under the regulatory control of
the PDGF-b promoter has been shown to result in motor
deﬁcits, dopaminergic loss, and formation of inclusion
bodies (Masliah et al. 2000). Mice with the highest levels
of expression (line D) showed intraneuronal accumulation
of a-syn that started at 3 months of age and was accom-
panied by the loss of tyrosine hydroxylase (TH) ﬁbers in
the caudoputamen region and synapses in the temporal
cortex. Although no apparent neuronal loss was detected in
the substantia nigra (SN), measurements of dopamine
levels in the caudoputamen region showed a 25–50%
reduction at 12 months of age. Consistent with these
results, tg mice showed mild to moderate motor deﬁcits in
the rotarod, particularly in mice with the greatest loss of
dopamine, indicating that more substantial deﬁcits ([75%)
of this transmitter might be necessary for more overt def-
icits to appear. In mThy-1-hasyn tg mice, this protein
accumulated in synapses and neurons throughout the brain,
including the thalamus, basal ganglia, SN, and brainstem
(Rockenstein et al. 2002; Fleming et al. 2004).
Because previous studies have shown that mutations
associated with familial parkinsonism accelerate a-syn
aggregation and oligomerization (Conway et al. 1998;
Narhi et al. 1999), we compared the patterns of neurode-
generation, a-syn aggregation, and neurological alterations
in tg mice expressing wt or mutant (A53T) ha-syn at
comparable levels under the PDGF-b promoter. Remark-
ably, we found that mice expressing low levels of mutant
ha-syn developed progressive motor deﬁcits and neurode-
generation associated with ha-syn accumulation in syn-
apses and neurons, but very few or no inclusions were
found (Hashimoto et al. 2003a). Similarly, mice expressing
high levels of mutant A53T, but not wt or A30P mutant,
a-syn developed a severe and complex motor impairment
leading to paralysis and death (Giasson et al. 2002; Lee
et al. 2002; von Coelln et al. 2006). In contrast to our
model expressing low levels of mutant a-syn, animals
expressing higher levels of A53T a-syn developed age-
dependent intracytoplasmic neuronal a-syn inclusions
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123paralleling disease onset, and the a-syn inclusions reca-
pitulated features of human disorders. Moreover, immu-
noelectron microscopy revealed that the a-syn inclusions
contained 10–16 nm wide ﬁbrils similar to human patho-
logical inclusions. These mice demonstrate that A53T
a-syn leads to the formation of toxic ﬁlamentous a-syn
neuronal inclusions that cause neurodegeneration (Giasson
et al. 2002).
This spectrum of a-syn-associated neurodegenerative
phenotypes in various tg models can be partially attributed
to the different effects conferred by expressing mutant
versus wt a-syn. Another important factor is the promoters
selected to drive a-syn expression, which regulate both
expression levels and cell-type speciﬁcity. For example,
under the mThy-1 promoter, expression of either wt or
mutant a-syn (van der Putten et al. 2000) results in
extensive insoluble a-syn accumulation throughout the
CNS including, in some cases, in the SN or motor neurons
(Rockenstein et al. 2002). Under the mouse PrP promoter,
expression of mutant A53T a-syn enhanced the accumu-
lation of aggregation-promoting C-terminally truncated
species of a-syn (Li et al. 2005). Under the rat TH pro-
moter, expression of double mutant ha-syn adversely
affects the integrity of dopaminergic terminals and leads to
age-related declines in motor coordination and dopami-
nergic markers (Richﬁeld et al. 2002).
Further studies to investigate the role of a-syn mutations
and selective neuronal vulnerability in the SN have been
performed in rats utilizing lentiviral and adeno-associated-
viral vectors (Kirik et al. 2002; Klein et al. 2002;L o
Bianco et al. 2002). In contrast to tg mice models, a
selective loss of nigral dopaminergic neurons associated
with a dopaminergic denervation of the striatum was
observed in animals expressing either wt or mutant forms
of ha-syn. This neuronal degeneration correlates with the
appearance of abundant a-syn-positive inclusions and
extensive neuritic pathology detected with both a-syn and
silver staining. Rat a-syn similarly leads to protein aggre-
gation but without cell loss, suggesting that inclusions are
not the primary cause of cell degeneration in PD (Lo Bi-
anco et al. 2002).
In summary, these in vivo models support the contention
that a-syn-dependent neurodegeneration is associated with
abnormal accumulation of detergent-insoluble a-syn
(probably representing oligomeric forms) rather than with
inclusion formation representing ﬁbrillar polymeric a-syn.
The speciﬁc accumulation of detergent-insoluble a-syn in
these tg mice recapitulates a pivotal feature of LBD (Kahle
et al. 2001) and it is of signiﬁcant importance in the future
development and evaluation of novel treatments.
Disease Targets and Ligands for Combined AD and PD
a-Synuclein as a Target in Combined AD/PD
a-Synuclein was originally identiﬁed in AD plaques as the
precursor protein of the non-Ab component (NAC) of AD
amyloid (Fig. 4a) and thus was called non-amyloid compo-
nent of plaques (NACP) (Ueda et al. 1993; Iwai et al. 1995a;
Masliahetal.1996a;Iwai2000).NAC,ahighlyhydrophobic
35-amino acid domain within the a-syn molecule, may be
involved in amyloid formation (Iwai et al. 1995a) (Fig. 3).
NAC is highly amyloidogenic and aggregates to form ﬁbrils
under oxidative conditions (Hashimoto et al. 1997;
Hashimoto et al. 1999), and NAC also interacts with Ab and
promotes Ab aggregation (Yoshimoto et al. 1995).
Remarkably, several studies have now conﬁrmed that
the pathology of AD and PD overlap in a heterogeneous
group of conditions denominated jointly LBD (McKeith
2000; Lippa et al. 2007). Approximately 25% of all cases
of AD develop parkinsonism and about 50% of all cases of
PD develop AD-type dementia after 65 years of age
(Hansen et al. 1990). Moreover, 70% of patients with
Fig. 4 Characteristics of a-syn aggregates and inclusions in the
brains of AD patients. a Representative section from the brain of an
AD patient immunostained with an antibody against the NAC region
of a-syn. The staining shows characteristic plaques composed of Ab
protein. b Representative section from the brain of an AD patient
immunostained with an antibody against a-syn that detected Lewy
body-like inclusions in the neocortex. c Representative section from
the brain of an AD patient double immunolabeled with antibodies
against Ab and a-syn shows co-localization of the two signals in
plaques. Scale bar, 20 lm( a), 10 lm( b, c)
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123sporadic AD display the formation of a-syn-positive
LB-like inclusions in the amygdala and limbic structures
(Lippa et al. 1998; Trojanowski et al. 1998; Hamilton
2000) and by the time of autopsy, approximately 90% of
patients with probable LBD also meet the Reagan patho-
logic criteria for AD (Hyman and Trojanowski 1997;
McKeith et al. 2005). Similarly, in patients with FAD and
Down’s syndrome, LB-like pathology and parkinsonism
have been reported (Lippa et al. 1999). Interestingly, the
brains of patients with DLB and PDD display very similar
pathology, with the exception that recent studies have
shown extensive deposition of Ab and a-syn in the striatum
and hippocampus in DLB compared to only a-syn in PDD
cases (Duda et al. 2002; Jellinger and Attems 2006). Fur-
thermore, previous studies provide extensive support for an
interaction between pathogenic pathways in AD and PD, in
particular FAD cases with presenilin mutations that present
with signiﬁcant LB pathology (Rosenberg 2005; Snider
et al. 2005; Leverenz et al. 2006). The amyloidogenic
fragment, NAC, of a-syn is found in the amyloid plaque
(Hashimoto et al. 2000) (Fig. 4a), although some contro-
versy has emerged in this respect (Culvenor et al. 1999).
The dystrophic neurites in the plaques from AD patients
display intense a-syn immunoreactivity (Masliah et al.
1996a) (Fig. 4), a-syn-positive aggregates are found in
limbic regions in AD (Lippa et al. 1999) (Fig. 4b) and the
overall levels of a-syn are abnormal in the early stages of
AD (Iwai et al. 1996). Moreover, genetic polymorphisms in
the a-syn gene have been shown to regulate the suscepti-
bility to AD (Xia et al. 1996; Tsigelny et al. 2008).
Underlying interactions between a-syn and Ab play a
fundamental role in the pathogenesis of LBD (Lippa et al.
1998; Hashimoto et al. 2000; Masliah et al. 2001; Plet-
nikova et al. 2005). Speciﬁcally, Ab worsens the deﬁcits
associated with a-syn accumulation (Pettegrew 1989;
Lippa et al. 1998; Lippa et al. 2005; Pletnikova et al. 2005;
Deramecourt et al. 2006; Mandal et al. 2006; Lippa et al.
2007), and Ab promotes the oligomerization and toxic
conversion of a-syn (Masliah et al. 2001; Mandal et al.
2006) (Fig. 5), suggesting that Ab and a-syn might directly
interact in vitro and in vivo. In support of this possibility,
under pathological conditions, both aggregated Ab and
a-syn might associate with membranes and accumulate in
caveolae (Soto et al. 1994; Bouillot et al. 1996; Eliezer
et al. 2001; Fortin et al. 2004; Kubo et al. 2005; Bar-On
et al. 2006; Kim et al. 2006; Bar-On et al. 2008; Wil-
liamson et al. 2008). Consistent with these ﬁndings, our
recent studies have shown that Ab and a-syn co-localize in
membrane and caveolar fractions, and Ab stabilizes a-syn
multimers that might form channel-like structures in the
membrane (Tsigelny et al. 2008). Moreover, lipid rafts in
the membrane have been postulated to play a role in
oligomerization of misfolded proteins (Soto et al. 1994;
Kazlauskaite and Pinheiro 2005; Kim et al. 2006) including
a-syn (Fortin et al. 2004; Bar-On et al. 2006; Bar-On et al.
2008) and Ab (Soto et al. 1994; Kim et al. 2006; Wil-
liamson et al. 2008) and might represent a suitable site for
the abnormal interactions between aggregated forms of
a-syn and Ab. Furthermore, highly amyloidogenic intran-
euronal Ab (Wilson et al. 1999) has been shown to accu-
mulate in the endoplasmic reticulum (Cook et al. 1997;
Hartmann et al. 1997), Golgi apparatus (Xu et al. 1997; Xia
et al. 2000), and the endosome–lysosome system (Koo and
Squazzo 1994), and these organelles may provide addi-
tional sites for interaction between Ab and a-syn. In sup-
port of this possibility, aggregated forms of Ab and a-syn
have been independently described in several intracellular
membranous structures (Bahr and Bendiske 2002;
Hashimoto et al. 2003b; Lee et al. 2005; Nixon and Cataldo
2006); (Tsigelny et al. 2007).
Mechanisms of Neurodegeneration and Interactions
Between a-syn and Ab in Combined AD/PD
The aggregates of a-syn might independently contribute to
the neurodegenerative process in AD or via interactions
with Ab. Most studies have investigated the formation of
toxic oligomeric species derived from homologous mono-
mers. We have recently investigated the interactions
between heterogeneous proteins that can form toxic hybrid
oligomers, showing that Ab and a-syn can interact in vivo
and in vitro (Tsigelny et al. 2008). Supporting these ﬁnd-
ings, Ab and a-syn co-immunoprecipitated in the brains of
patients with LBD as well as in double APP/a-syn trans-
genic (tg) mice. Furthermore, molecular modeling studies
showed that these interactions promoted the formation of
Fig. 5 Molecular dynamics of a-syn and Ab interactions leading to
the formation of hybrid pores in the membrane. a Conformation of
a-syn dimer in the presence of one molecule of Ab. b Conformation
of a-syn trimer with the Ab monomer. c Conformation of a-syn
pentamer with the Ab monomer and the formation of a central pore-
like channel. d Space-ﬁlled model showing the pore-like a-syn
pentamer with the Ab monomer embedded in a membrane
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123highly stable ring-like oligomers composed of both Ab and
a-syn and these species dock in the membrane (Fig. 5).
Similarly, in vitro studies conﬁrmed that both freshly sol-
ubilized as well as aggregated Ab and a-syn can directly
interact and form hybrid ring-like structures.
In agreement with this possibility, a previous study
showed that Ab promotes the aggregation of a-syn in vivo
and worsens the deﬁcits in a-syn tg mice (Masliah et al.
2001). Moreover, a-syn has also been shown to accumulate
in the brains of APP tg (Yang et al. 2000) and APP/
presenilin-1 (PS1) double tg mice that produce large
amounts of Ab (Kurata et al. 2007). In addition, as
described in the previous section, several studies have now
shown that in the brains of LBD patients, Ab contributes to
the levels and state of a-syn aggregation and LB formation
(Pettegrew 1989; Lippa et al. 1998; Lippa et al. 2005;
Pletnikova et al. 2005; Deramecourt et al. 2006; Mandal
et al. 2006; Lippa et al. 2007). Taken together, these studies
in tg mice and human brains support the contention that Ab
and a-syn interact in vivo and that these interactions are of
signiﬁcance in the pathogenesis of the disease.
Ab might promote a-syn aggregation by directly inter-
acting with a-syn molecules bound to the membrane and
therefore facilitating the formation of more stable oligo-
mers. However, Ab might promote a-syn aggregation
through other pathways, including increased oxidative
stress, calpain activation with C-terminal cleavage of a-syn
(Mishizen-Eberz et al. 2005; Dufty et al. 2007), and
aberrant phosphorylation induced by secreted forms of Ab.
The hybrid multimers of Ab and a-syn might embed in
the membrane (Fig. 5d) of mitochondria, lysosomes, and
the plasma membrane, leading to the formation of nano-
pore-like structures resulting in abnormal ion conductance
(Tsigelny et al. 2008). Previous studies have shown that Ab
penetrates in the membrane and aggregates to form chan-
nels that facilitate the abnormal trafﬁcking of cations such
as Ca
2? and K
? (Arispe et al. 1993; Arispe et al. 1996; Lin
et al. 2001; Mattson 2007). Studies of a-syn aggregation by
atomic force microscopy have shown that the oligomers
form heterogeneous pore-like structures that might induce
cell death via disruption of calcium homeostasis (Quist
et al. 2005; Danzer et al. 2007).
Next Frontiers in Drug Discovery
Alterations in the balance between factors promoting
aggregation, clearance, and synthesis of Ab and a-syn
might be centrally involved in the formation of oligomers
and the pathogenesis of neurodegeneration. Clearance of
Ab and a-syn oligomers occurs primarily via degrading
enzymes (neprilysin), chaperone molecules (b-syn, HSP27,
70), and lysosomal pathways (autophagy). Immunotherapy
approaches might reduce a-syn accumulation by stimulat-
ing autophagy. Gene therapy approaches using viral vec-
tors can be used to target these pathways involved in Ab
and a-syn clearance. For example, delivery of neprilysin,
an Ab-degrading enzyme, into the brains of APP tg mice
results in amelioration of the behavioral deﬁcits, improved
synaptic formation, and decreased Ab accumulation. Since
Ab also promotes the aggregation of a-syn, gene therapy
delivery of neprilysin has also been shown to reduce the a-
syn pathology and deﬁcits in tg mice expressing both APP
and a-syn. Another important clearance mechanism ame-
nable for manipulation by gene therapy is the autophagy
pathway. For this lysosomal degradation system, the olig-
omers are targeted to the chaperone-mediated system or to
the macroautophagy pathway. In both AD and PD the
autophagy pathway is abnormal. Therefore increasing
autophagy with mTor antagonists and gene therapy to
promote autophagy might be of therapeutical value. Such
pro-clearance properties might also provide a novel strat-
egy for the treatment of other neurodegenerative disorders.
Conclusions
In combined AD/PD, both Ab and a-syn might directly
interact under pathological conditions leading to the for-
mation of toxic oligomers and nanopores that increase
intracellular calcium. Other mechanisms involved include
oxidative stress, lysosomal leakage, and mitochondrial
dysfunction. Thus, better understanding the steps involved
in the process of Ab and a-syn aggregation is important in
order to develop intervention strategies that might prevent
or reverse the toxic conversion in AD.
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